Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Bristol is expanding its CAR-T cell development into new indications.

Bristol-Myers Squibb Co., after completing its acquisition of Celgene Corp., is attempting to position itself as a developer of best-in-class and first-in-class chimeric antigen receptor T-cell (CAR-T) therapies for lymphoma and multiple myeloma, including the CD19-targeting lisocabtagene maraleucel (JCAR017, liso-cel) and idecabtagene vicleucel (ide-cel, bb2121) against B-cell maturation antigen (BCMA).

The company presented pivotal trial results in relapsed and refractory B-cell lymphoma for its first CAR-T therapy, liso-cel, at the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D